ConductScience.org, home
Diseases
API referenceFor AI assistants

Disease · MONDO_0004952

Hodgkins lymphoma

6 sourcesdiseases-2026-09-18-0.1.0

Download JSON
Cite this record

ConductScience Library. Hodgkins lymphoma. Diseases, record MONDO_0004952. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0004952

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name
Hodgkins lymphoma
Open Targets
Open Targets ID
MONDO_0004952
Open Targets
Other names
HL, Hodgkin disease, Hodgkin lymphoma, Hodgkin's Disease, Hodgkin's lymphoma, Hodgkin's sarcoma, classical Hodgkin's lymphoma
Open Targets
Disease Ontology
DOID:8567
Disease Ontology
MeSH
D006689
MeSH
NCI Thesaurus
C9357
NCI Thesaurus
Orphanet
ORPHA:98293
Orphanet
Highest stage of its drugs
Approval, for 18 of its 201 drugs, from DailyMed, EMA Human Drugs, PMDA and TTD
Open Targets

Drugs201

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

DrugChEMBL IDTypeOpen Targets' stageStage reported byReportsOf them trialsTrials shown hereSource
CYCLOPHOSPHAMIDECHEMBL1200796Small moleculeApprovalDailyMed949393Drugs and targets
BRENTUXIMAB VEDOTINCHEMBL1742994Antibody drug conjugateApprovalDailyMed, EMA Human Drugs, PMDA and TTD797474Drugs and targets
DACARBAZINECHEMBL476Small moleculeApprovalDailyMed646262Drugs and targets
BLEOMYCINCHEMBL6067492ApprovalTTD484747Drugs and targets
MELPHALANCHEMBL852Small moleculeApprovalEMA Human Drugs403939Drugs and targets
DOXORUBICIN HYDROCHLORIDECHEMBL359744Small moleculeApprovalDailyMed393636Drugs and targets
CARMUSTINECHEMBL513Small moleculeApprovalDailyMed and EMA Human Drugs312929Drugs and targets
NIVOLUMABCHEMBL2108738AntibodyApprovalEMA Human Drugs and PMDA302828Drugs and targets
PROCARBAZINECHEMBL1321Small moleculeApprovalTTD181717Drugs and targets
PEMBROLIZUMABCHEMBL3137343AntibodyApprovalEMA Human Drugs161514Drugs and targets

1 to 10 of 201

See all 201 drugs

Targets189

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

TargetProteinIts drugs that act on itMechanismsHighest stage of those drugsGene in GenesSource
TOP2ADNA topoisomerase 2-alpha9DNA topoisomerase II alpha inhibitor; DNA topoisomerase II inhibitorApprovalhttps://conductscience.org/library/genes/7153Drugs and targets
TUBA1ATubulin9Tubulin inhibitorApprovalhttps://conductscience.org/library/genes/7846Drugs and targets
TUBA1BTubulin9Tubulin inhibitorApprovalhttps://conductscience.org/library/genes/10376Drugs and targets
TUBA1CTubulin9Tubulin inhibitorApprovalhttps://conductscience.org/library/genes/84790Drugs and targets
TUBA3CTubulin9Tubulin inhibitorApprovalhttps://conductscience.org/library/genes/7278Drugs and targets
TUBA3ETubulin9Tubulin inhibitorApprovalhttps://conductscience.org/library/genes/112714Drugs and targets
TUBA4ATubulin9Tubulin inhibitorApprovalhttps://conductscience.org/library/genes/7277Drugs and targets
TUBBTubulin9Tubulin inhibitorApprovalhttps://conductscience.org/library/genes/203068Drugs and targets
TUBB1Tubulin9Tubulin inhibitorApprovalhttps://conductscience.org/library/genes/81027Drugs and targets
TUBB2ATubulin9Tubulin inhibitorApprovalhttps://conductscience.org/library/genes/7280Drugs and targets

1 to 10 of 189

See all 189 targets

Trials425

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 4 more are not shown, since the checks do not confirm them.

TrialTitlePhaseParticipantsResults first postedConditionsDrugsLinked bySource
NCT00025259Chemotherapy With or Without Additional Chemotherapy and/or Radiation Therapy in Treating Children With Newly Diagnosed Hodgkin's DiseasePhase 31,7342017-03-07
Childhood Lymphocyte-Depleted Classical Hodgkin Lymphoma, Childhood Mixed Cellularity Classical Hodgkin Lymphoma, Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma, Childhood Nodular Sclerosis Classical Hodgkin Lymphoma, Stage I Childhood Hodgkin Lymphoma, Stage II Childhood Hodgkin Lymphoma, Stage III Childhood Hodgkin Lymphoma, Stage IV Childhood Hodgkin Lymphoma
BLEOMYCIN SULFATE, CISPLATIN, CYCLOPHOSPHAMIDE, CYTARABINE, DEXAMETHASONE, DOXORUBICIN HYDROCHLORIDE, ETOPOSIDE, FILGRASTIM, PREDNISONE, VINCRISTINE SULFATEIts record names the diseaseClinicalTrials.gov
NCT01712490A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin LymphomaPhase 31,3342018-11-27Hodgkin LymphomaBLEOMYCIN, BRENTUXIMAB VEDOTIN, DACARBAZINE, DOXORUBICIN, VINBLASTINEIts record names the diseaseClinicalTrials.gov
NCT03907488Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin LymphomaPhase 39942025-06-12
Ann Arbor Stage III Hodgkin Lymphoma, Ann Arbor Stage III Lymphocyte-Depleted Classic Hodgkin Lymphoma, Ann Arbor Stage III Mixed Cellularity Classic Hodgkin Lymphoma, Ann Arbor Stage III Nodular Sclerosis Classic Hodgkin Lymphoma, Ann Arbor Stage IV Hodgkin Lymphoma, Ann Arbor Stage IV Lymphocyte-Depleted Classic Hodgkin Lymphoma, Ann Arbor Stage IV Mixed Cellularity Classic Hodgkin Lymphoma, Ann Arbor Stage IV Nodular Sclerosis Classic Hodgkin Lymphoma, Classic Hodgkin Lymphoma, Lymphocyte-Rich Classic Hodgkin Lymphoma
BRENTUXIMAB VEDOTIN, DACARBAZINE, DOXORUBICIN HYDROCHLORIDE, NIVOLUMAB, VINBLASTINE SULFATEIts record names the diseaseClinicalTrials.gov
NCT00003389Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's LymphomaPhase 38542015-09-03LymphomaBLEOMYCIN, CYCLOPHOSPHAMIDE, DACARBAZINE, DOXORUBICIN, ETOPOSIDE, MECHLORETHAMINE, PREDNISONE, VINBLASTINE, VINCRISTINEIts record names the diseaseClinicalTrials.gov
NCT00345865Autologous Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's LymphomaPhase 24732020-07-14LymphomaCARBOPLATIN, CARMUSTINE, CYCLOPHOSPHAMIDE, ETOPOSIDE, FILGRASTIM, IFOSFAMIDE, MELPHALAN, RITUXIMABIts record names the diseaseClinicalTrials.gov
NCT00074490Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph CancersPhase 24422018-12-31Lymphoma, Leukemia, Myeloproliferative Disorders, Multiple Myleoma, Myelodysplastic SyndromeSIROLIMUSIts record names the diseaseClinicalTrials.gov
NCT00822120S0816 Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin LymphomaPhase 23712018-04-04Lymphoma, Nonneoplastic ConditionBLEOMYCIN SULFATE, CYCLOPHOSPHAMIDE, DACARBAZINE, DOXORUBICIN HYDROCHLORIDE, ETOPOSIDE, FILGRASTIM, PREDNISONE, PROCARBAZINE HYDROCHLORIDE, VINBLASTINE SULFATE, VINCRISTINE SULFATEIts record names the diseaseClinicalTrials.gov
NCT01100502A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial)Phase 33292015-11-11Disease, HodgkinBRENTUXIMAB VEDOTINIts record names the diseaseClinicalTrials.gov
NCT01592370An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple MyelomaPhase 1/23202022-02-17Non-Hodgkin's Lymphoma, Hodgkin Lymphoma, Multiple MyelomaDARATUMUMAB, DEXAMETHASONE, IPILIMUMAB, LIRILUMAB, NIVOLUMAB, POMALIDOMIDEIts record names the diseaseClinicalTrials.gov
NCT00145600Therapy for Pediatric Hodgkin LymphomaPhase 22962013-05-07Hodgkin LymphomaCYCLOPHOSPHAMIDE, DOXORUBICIN, METHOTREXATE, PREDNISONE, VINBLASTINE, VINCRISTINEIts record names the diseaseClinicalTrials.gov

1 to 10 of 425

See all 425 trials

Comparisons in its trials92

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

ComparisonGroup 1, with the outcomeGroup 2, with the outcomeParticipantsTrialSource
A+AVD vs ABVD: Number of Participants With Abnormal Clinical Laboratory Values662 of 662658 of 6591,321NCT01712490Trial comparisons
A+AVD vs ABVD: deaths from any cause9 of 66213 of 6591,321NCT01712490Trial comparisons
A+AVD vs ABVD: serious adverse events284 of 662178 of 6591,321NCT01712490Trial comparisons
Arm I (Chemotherapy, Nivolumab, Radiation) vs Arm II (Chemotherapy, Brentuximab Vedotin, Radiation): Overall Survival7 of 48714 of 483970NCT03907488Trial comparisons
Arm I (Chemotherapy, Nivolumab, Radiation) vs Arm II (Chemotherapy, Brentuximab Vedotin, Radiation): Event-free Survival (EFS)52 of 48791 of 483970NCT03907488Trial comparisons
Arm I (Chemotherapy, Nivolumab, Radiation) vs Arm II (Chemotherapy, Brentuximab Vedotin, Radiation): Progression Free Survival (PFS)41 of 48781 of 483970NCT03907488Trial comparisons
Arm I (Chemotherapy, Nivolumab, Radiation) vs Arm II (Chemotherapy, Brentuximab Vedotin, Radiation): deaths from any cause7 of 48714 of 483970NCT03907488Trial comparisons
Arm I (Chemotherapy, Nivolumab, Radiation) vs Arm II (Chemotherapy, Brentuximab Vedotin, Radiation): serious adverse events140 of 48118 of 476957NCT03907488Trial comparisons
Arm A (ABVD) vs Arm B (Stanford V): serious adverse events355 of 414401 of 422836NCT00003389Trial comparisons
Arm A (ABVD) vs Arm B (Stanford V): Incidence of Second Cancers15 of 39519 of 399794NCT00003389Trial comparisons

1 to 10 of 92

See all 92 comparisons in its trials

Papers from its trials265

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMIDListed asTrials listing itSource
42644287RESULT1PubMed
30658935RESULT1PubMed
29234922RESULT1PubMed
29229594RESULT1PubMed
27297790RESULT1PubMed
27191266RESULT1PubMed
25895027RESULT1PubMed
25796459RESULT1PubMed
24642247RESULT1PubMed
24591201RESULT1PubMed

1 to 10 of 265

See all 265 papers from its trials

Data dates

The date of each source this release read.

Open Targets
2026-09-18
Open Targets
Drug links and their checks, from Drugs and targets
2026-09-18
Drugs and targets
ClinicalTrials.gov, from Trials
2026-11-12
Trials
Comparisons, from Trial comparisons
2026-03-23
Trial comparisons
PubMed, for the checks
2026-11-06
PubMed
MeSH, for the checks
2026-11-10
MeSH

Sources 6

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • NLM's MeSHNLM's terms
  • Open TargetsCC0 1.0
  • PubMedNLM's terms
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • NLM's MeSHNLM's
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0004952

GET https://conductscience.org/api/diseases/v1/MONDO_0004952/drugs?page=2

API referenceFor AI assistants